0000899243-18-012335.txt : 20180510
0000899243-18-012335.hdr.sgml : 20180510
20180510161222
ACCESSION NUMBER: 0000899243-18-012335
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180508
FILED AS OF DATE: 20180510
DATE AS OF CHANGE: 20180510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DOYLE WILLIAM F
CENTRAL INDEX KEY: 0001194459
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37565
FILM NUMBER: 18822641
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Novocure Ltd
CENTRAL INDEX KEY: 0001645113
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: LE MASURIER HOUSE, LA RUE LE MASURIER
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4YE
BUSINESS PHONE: 44 (0)15 3475 6700
MAIL ADDRESS:
STREET 1: LE MASURIER HOUSE, LA RUE LE MASURIER
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4YE
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-08
0
0001645113
Novocure Ltd
NVCR
0001194459
DOYLE WILLIAM F
C/O NOVOCURE INC.
20 VALLEY STREAM PARKWAY, SUITE 300
MALVERN
PA
19355
1
1
0
0
Executive Chairman
Ordinary Shares
2018-05-08
4
F
0
28756
28.055
D
940795
D
Ordinary Shares
2018-05-09
4
F
0
28652
28.257
D
912143
D
Ordinary Shares
43000
I
WFD Ventures Fund II, L.P.
Ordinary Shares
625954
I
WFD-GP II, LLC
293,840 restricted stock units ("RSUs") vested on May 2, 2018. The issuer released one-fifth of the RSUs (58,768 RSUs) as of May 3, 2018 (previously reported on a Form 4 filed on May 4, 2018), released one-fifth of the RSUs as of May 4, 2018 and one-fifth of the RSUs as of May 7, 2018 (previously reported on a Form 4 filed on May 8, 2018), and released an additional one-fifth of the RSUs as of May 8, 2018 and one-fifth of the RSUs as of May 9, 2018. Mr. Doyle has sold sufficient RSUs to cover the tax liability. One-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017.
Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of fully-vested restricted stock units ("RSUs") granted by the issuer to the reporting person and reported on a Form 4 filed on May 4, 2017.
Mr. Doyle is the Managing Director of WFD Ventures LLC, the sole member of WFD-GP II LLC, which is the general partnerof WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest.
/s/ William F. Doyle
2018-05-10